|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||125.79 - 127.02|
|52 Week Range||87.49 - 130.29|
|PE Ratio (TTM)||95.04|
|Earnings Date||Apr 25, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||116.00|
PALO ALTO, Calif. , April 20, 2018 /PRNewswire/ -- Varian (NYSE: VAR) today announced it has received FDA 510(k) clearance for its Calypso ® Anchored Beacon ® transponder. Used with a Varian TrueBeam ® ...
PALO ALTO, Calif. , April 19, 2018 /PRNewswire/ -- Varian (NYSE: VAR) today announced it will be showcasing the expanded imaging and treatment capabilities of the Halcyon ™ system and the new version of ...
PALO ALTO, Calif. , April 19, 2018 /PRNewswire/ -- Varian (NYSE: VAR) today announced it is incorporating new imaging technologies in the Halcyon ™ 2.0 treatment system to expand its capabilities and ability ...
PALO ALTO, Calif., April 18, 2018 /PRNewswire/ -- Varian (VAR) today announced it received the "Best After-Sales Service Performance Award for Radiotherapy Products" in the annual Chinese Medical Devices Industry Data and After-Sales Service Survey. The survey, which has been conducted annually for the last eight years, is organized by China Medical Equipment magazine, published by People's Medical Publishing House Co., Ltd., Health News, as well as several industry associations including the Medical Engineering Branch of the Chinese Medical Association and the Clinical Engineering Branch of the Chinese Medical Doctors Association. It is one of the most influential medical industry performance evaluations conducted in China.
The introduction of Velocity 4.0 is in line with Varian Medical's (VAR) strategy to target the radiation-dosimetry market. The platform will help patients with liver malignancies.
Here we take a peek at Varian Medical's (VAR) performance to analyze why investors should hold on to this stock despite adversities.
Additionally, this was an improvement in sentiment as investors who seek to profit from falling equity prices reduced their short positions on February 2. Over the last one-month, outflows of investor capital in ETFs holding VAR totaled $16.57 billion.
Software has received FDA 510(k) clearance PALO ALTO, Calif. , April 9, 2018 /PRNewswire/ -- Varian (NYSE: VAR) today announced a new version of its Velocity ™ cancer imaging software which includes ...
Should Investors Be Interested in Varian Medical Systems? Varian Medical Systems’ (VAR) HyperArc is an end-to-end, high-definition, intracranial radiotherapy solution. Since the launch of this radiotherapy solution in 4Q16, the company has secured 57 orders, of which 19 were placed in 1Q18.
Should Investors Be Interested in Varian Medical Systems? In 1Q18, Varian Medical Systems (VAR) reported revenues of $356.7 million from the Americas region, which was a YoY (year-over-year) growth of 20% on a reported as well as constant currency basis. The company reported revenue of $193 million from EMEA (Europe, the Middle East, and Africa) sales in 1Q18, which is a YoY rise of 5% on a reported basis but a decline of 2% on a constant currency basis.
Should Investors Be Interested in Varian Medical Systems? In 1Q18, Varian Medical Systems (VAR) reported new orders worth $620 million for its oncology systems business. It had a total order backlog worth $2.7 billion at the end of 1Q18, which is a YoY rise of 7%.
Should Investors Be Interested in Varian Medical Systems? In 1Q18, Varian Medical Systems (VAR) reported revenues of $679 million, which is a YoY (year-over-year) rise of 13% on a reported basis and an 11% rise on a constant currency basis. It was mainly driven by increased sales of its linac (linear accelerator) systems in the oncology operating segment.
PALO ALTO, Calif., March 27, 2018 /PRNewswire/ -- Varian (VAR) today announced customers using Varian Eclipse™ treatment planning software placed the highest in the overall category in the first ever World Championships of Treatment Planning, hosted by ProKnow. In addition to the top four and six of the top 10 positions in the overall category, Eclipse customers also had the top three scoring VMAT plans.
On March 14, 2018, Varian Medical Systems (VAR) announced that its acquisition of Sirtex Medical (SXMDF) has received regulatory clearances from the US antitrust authorities as well as the FCO (German Federal Cartel Office). The acquisition was announced on January 29, 2018, and entails the acquisition of all outstanding shares of Sirtex Medical by Varian Medical Systems for $1.3 billion.